Additionally, this finding opens the door to potentially investigating BSO combined with AVA as a means to overcome chemo- and radioresistance in STSs with high GPx1/glutathione, especially with a clinical trial reporting potentially enhanced responses to melphalan in neuroblastomas with elevated glutathione [65]. Here, GPX1 is linked to neuroblastoma.